An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Clinical trial NCT05667493 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05667493
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-30
- Primary completion
- 2029-08-01
- Enrollment
- 1400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.